BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19786980)

  • 21. Polymorphisms in GSTM1 and XPD genes predict clinical outcome in advanced oral cancer patients treated with postoperative radiotherapy.
    Mahimkar MB; Samant TA; Kannan S; Tulsulkar J; Pai PS; Anantharaman D
    Mol Carcinog; 2012 Oct; 51 Suppl 1():E94-103. PubMed ID: 22213390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
    Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
    J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of XRCC1, GSTP1, and GSTM1 Polymorphisms on the Survival of Ovarian Carcinoma Patients Treated with Chemotherapy.
    Zhai XH; Huang J; Wu FX; Zhu DY; Wang AC
    Oncol Res Treat; 2016; 39(7-8):440-6. PubMed ID: 27487108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glutathione S-transferase M1, T1 and P1 polymorphisms: susceptibility and outcome in lung cancer patients.
    Sreeja L; Syamala V; Hariharan S; Syamala VS; Raveendran PB; Sivanandan CD; Madhavan J; Ankathil R
    J Exp Ther Oncol; 2008; 7(1):73-85. PubMed ID: 18472644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol.
    Silvestrini R; Daidone MG; Veneroni S; Benini E; Scarfone G; Zanaboni F; Villa A; Presti M; Danese S; Bolis G
    Cancer; 1998 Jan; 82(1):159-67. PubMed ID: 9428493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
    J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphisms in DNA repair genes XPD and XRCC1 and p53 mutations in lung carcinomas of never-smokers.
    Gao WM; Romkes M; Siegfried JM; Luketich JD; Keohavong P
    Mol Carcinog; 2006 Nov; 45(11):828-32. PubMed ID: 16865671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer.
    Kim K; Kang SB; Chung HH; Kim JW; Park NH; Song YS
    Gynecol Oncol; 2008 Dec; 111(3):509-15. PubMed ID: 18851872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer.
    Santos AM; Sousa H; Portela C; Pereira D; Pinto D; Catarino R; Rodrigues C; Araújo AP; Lopes C; Medeiros R
    Biochem Biophys Res Commun; 2006 Feb; 340(1):256-62. PubMed ID: 16364249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of glutathione-S-transferase polymorphisms in ovarian cancer survival.
    Nagle CM; Chenevix-Trench G; Spurdle AB; Webb PM
    Eur J Cancer; 2007 Jan; 43(2):283-90. PubMed ID: 17084623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy.
    Rajkumar T; Samson M; Rama R; Sridevi V; Mahji U; Swaminathan R; Nancy NK
    Breast Cancer Res Treat; 2008 Nov; 112(1):81-7. PubMed ID: 18058229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
    Ruzzo A; Graziano F; Loupakis F; Rulli E; Canestrari E; Santini D; Catalano V; Ficarelli R; Maltese P; Bisonni R; Masi G; Schiavon G; Giordani P; Giustini L; Falcone A; Tonini G; Silva R; Mattioli R; Floriani I; Magnani M
    J Clin Oncol; 2007 Apr; 25(10):1247-54. PubMed ID: 17401013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association analysis of glutathione-S-transferase P1 (GSTP1) polymorphism with urothelial cancer susceptibility and myelosuppression after M-VAC chemotherapy.
    Yokomizo A; Yamamoto K; Kinukawa N; Tsunoda T; Koga H; Naito S
    Int J Urol; 2007 Jun; 14(6):500-4. PubMed ID: 17593093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients.
    Sweeney C; Nazar-Stewart V; Stapleton PL; Eaton DL; Vaughan TL
    Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):527-33. PubMed ID: 12814998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.
    Marsh S; Paul J; King CR; Gifford G; McLeod HL; Brown R
    J Clin Oncol; 2007 Oct; 25(29):4528-35. PubMed ID: 17925548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer.
    Gao WM; Romkes M; Day RD; Siegfried JM; Luketich JD; Mady HH; Melhem MF; Keohavong P
    Carcinogenesis; 2003 Oct; 24(10):1671-6. PubMed ID: 12844488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
    Kim JG; Sohn SK; Chae YS; Song HS; Kwon KY; Do YR; Kim MK; Lee KH; Hyun MS; Lee WS; Sohn CH; Jung JS; Kim GC; Chung HY; Yu W
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):355-60. PubMed ID: 19052714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inherited susceptibility to bleomycin-induced micronuclei: correlating polymorphisms in GSTT1, GSTM1 and DNA repair genes with mutagen sensitivity.
    Angelini S; Kumar R; Carbone F; Bermejo JL; Maffei F; Cantelli-Forti G; Hemminki K; Hrelia P
    Mutat Res; 2008 Feb; 638(1-2):90-7. PubMed ID: 17953974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.